Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
Frontiers in Immunology, 2021 The interaction of the Fc region of therapeutic antibodies and antibody-drug conjugates with Fcγ receptors (FcγRs) can lead to unpredictable and severe side effects.
Adrian Elter +7 more
doaj +1 more source
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells _in vitro_ and _in vivo_ [PDF]
, 2008 CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody (mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives _in ...
Benjamin Dä +20 more
core +1 more source
Selection Of A Novel Aptamer Against Vitronectin Using Capillary Electrophoresis And Next Generation Sequencing [PDF]
, 2016 Breast cancer (BC) results in ≃40,000 deaths each year in the United States and even among survivors treatment of the disease may have devastating consequences, including increased risk for heart disease and cognitive impairment resulting from the toxic ...
Boyacioglu, O. +8 more
core +3 more sources
A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2
Frontiers in Immunology, 2019 Despite substantial advances in the treatment of acute myeloid leukemia (AML), only 30% of patients survive more than 5 years. Therefore, new therapeutics are much needed.
Amanda C. Herrmann +13 more
doaj +1 more source
Immuno Magnetic Thermosensitive Liposomes For Cancer Therapy [PDF]
, 2019 The present work describes the encapsulation of the drug doxorubicin (DOX) in immuno paramagnetic thermosensitive liposomes. DOX is the most common chemotherapeutic agent for the treatment of a variety of carcinomas.
Alawak, Mohamad
core +1 more source
Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors [PDF]
, 2020 Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Chen, Liang +15 more
core +1 more source
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
Therapeutics and Clinical Risk Management, 2017 Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM
doaj
Frontiers in Immunology, 2021 Monoclonal antibodies directed against the CD20 surface antigen on B cells are widely used in the therapy of B cell malignancies. Upon administration, the antibodies bind to CD20 expressing B cells and induce their depletion via cell- and complement ...
Sina Bondza +9 more
doaj +1 more source
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]
, 2014 Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core +2 more sources
Human Monocyte Antibody-Dependent Cell-Mediated Cytotoxicity to Tumor Cells [PDF]
Journal of Clinical Investigation, 1978 Previous investigations of mononuclear cell antibody-dependent cell-mediated cytotoxicity (ADCC) toward tumor cells suggest that K lymphocytes and not monocytes are active in this cytotoxic reaction. This report, however, demonstrates that human monocytes are able to carry out ADCC toward three different human tumor cell lines (CEM T lymphoblasts, Raji
G M, Shaw, P C, Levy, A F, LoBuglio
openaire +2 more sources